These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19904485)

  • 1. The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.
    Leeb BF; Böttcher E; Brezinschek HP; Czerwenka C; Herold M; Hitzelhammer H; Mayrhofer F; Puchner R; Rainer F; Rintelen B; Schirmer M; Stuby U; Bröll H
    Clin Rheumatol; 2010 Feb; 29(2):167-74. PubMed ID: 19904485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G; Strehblow C; Fasching P
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.
    Fabbroni M; Cantarini L; Caso F; Costa L; Pagano VA; Frediani B; Manganelli S; Galeazzi M
    Mediators Inflamm; 2014; 2014():862969. PubMed ID: 25110401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.
    Fleischmann R; Iqbal I
    Drugs Aging; 2007; 24(3):239-54. PubMed ID: 17362051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
    Wiedmann MW; Mössner J; Baerwald C; Pierer M
    Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF alpha antagonist therapy and safety monitoring.
    Pham T; Bachelez H; Berthelot JM; Blacher J; Bouhnik Y; Claudepierre P; Constantin A; Fautrel B; Gaudin P; Goëb V; Gossec L; Goupille P; Guillaume-Czitrom S; Hachulla E; Huet I; Jullien D; Launay O; Lemann M; Maillefert JF; Marolleau JP; Martinez V; Masson C; Morel J; Mouthon L; Pol S; Puéchal X; Richette P; Saraux A; Schaeverbeke T; Soubrier M; Sudre A; Tran TA; Viguier M; Vittecoq O; Wendling D; Mariette X; Sibilia J
    Joint Bone Spine; 2011 May; 78 Suppl 1():15-185. PubMed ID: 21703545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K; Hartley L; Solanki K; White D
    N Z Med J; 2015 May; 128(1415):34-40. PubMed ID: 26117510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kang JH; Park DJ; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Lee SS
    J Korean Med Sci; 2014 Sep; 29(9):1205-11. PubMed ID: 25246737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.